JP2024520802A - ｕＰＡＲを標的とする抗原認識受容体及びその使用 - Google Patents

ｕＰＡＲを標的とする抗原認識受容体及びその使用 Download PDF

Info

Publication number
JP2024520802A
JP2024520802A JP2023575818A JP2023575818A JP2024520802A JP 2024520802 A JP2024520802 A JP 2024520802A JP 2023575818 A JP2023575818 A JP 2023575818A JP 2023575818 A JP2023575818 A JP 2023575818A JP 2024520802 A JP2024520802 A JP 2024520802A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520802A5 (enExample
Inventor
スコット ダブリュー． ロウ，
ミチェル サデライン，
ベガス， コリーナ アモル
ポール バルデレス，
イボ シー． ロレンツ，
ゼダ ジャン，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ
メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ
トライ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ, メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ, トライ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート， インコーポレイテッド filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2024520802A publication Critical patent/JP2024520802A/ja
Publication of JP2024520802A5 publication Critical patent/JP2024520802A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023575818A 2021-06-11 2022-06-10 ｕＰＡＲを標的とする抗原認識受容体及びその使用 Pending JP2024520802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209924P 2021-06-11 2021-06-11
US63/209,924 2021-06-11
PCT/US2022/032948 WO2022261398A1 (en) 2021-06-11 2022-06-10 Antigen recognizing receptors targeting upar and uses thereof

Publications (2)

Publication Number Publication Date
JP2024520802A true JP2024520802A (ja) 2024-05-24
JP2024520802A5 JP2024520802A5 (enExample) 2025-06-18

Family

ID=84425514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575818A Pending JP2024520802A (ja) 2021-06-11 2022-06-10 ｕＰＡＲを標的とする抗原認識受容体及びその使用

Country Status (7)

Country Link
US (1) US20240131070A1 (enExample)
EP (1) EP4351601A4 (enExample)
JP (1) JP2024520802A (enExample)
CN (1) CN117715648A (enExample)
AU (1) AU2022287975A1 (enExample)
CA (1) CA3221342A1 (enExample)
WO (1) WO2022261398A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520803A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
WO2026086712A1 (en) * 2024-10-22 2026-04-30 Peking University Upar targeting chimeric antigen receptors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145106A1 (en) * 2015-11-25 2017-05-25 Renzhi Wang Chimeric antigen receptor hCD87-CAR and applications thereof
CN110343665A (zh) * 2019-05-05 2019-10-18 吉林大学 一种新型car-t细胞及其应用
WO2020160518A1 (en) * 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
JP2024520803A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568428C (en) * 2004-05-25 2020-12-29 Attenuon, Llc Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145106A1 (en) * 2015-11-25 2017-05-25 Renzhi Wang Chimeric antigen receptor hCD87-CAR and applications thereof
WO2020160518A1 (en) * 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
CN110343665A (zh) * 2019-05-05 2019-10-18 吉林大学 一种新型car-t细胞及其应用
JP2024520803A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 583, JPN6026013275, 2020, pages 127 - 132, ISSN: 0005831992 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520803A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Also Published As

Publication number Publication date
EP4351601A1 (en) 2024-04-17
EP4351601A4 (en) 2025-07-02
AU2022287975A9 (en) 2024-01-25
AU2022287975A1 (en) 2023-12-14
CN117715648A (zh) 2024-03-15
US20240131070A1 (en) 2024-04-25
CA3221342A1 (en) 2022-12-15
WO2022261398A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
US20240374645A1 (en) Biologically relevant orthogonal cytokine/receptor pairs
AU2020216486B2 (en) Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker
AU2015357543B2 (en) Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
AU2022200052A1 (en) Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
CN107208047B (zh) 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
AU2020346824B2 (en) Chimeric orthogonal receptor proteins and methods of use
US20240123069A1 (en) Antigen recognizing receptors targeting upar and uses thereof
US20240131070A1 (en) Antigen recognizing receptors targeting upar and uses thereof
JP2018505174A (ja) キメラ抗原受容体、組成物及び方法
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
US20250319131A1 (en) Tunable cytokine receptor signaling domains
US20260034241A1 (en) Compositions and methods for in vivo expression of chimeric antigen receptors
WO2025193972A1 (en) Methods of using il-15 signaling to enhance nk and nk-like t cell function against aml
HK40109914A (zh) 抗egfrviii抗体、多肽、表达前述多肽的细胞、包含前述细胞的医药组合物、前述细胞的制造方法、及包含编码前述多肽的碱基序列的多核苷酸或载体
EA053037B1 (ru) Клетка, содержащая химерные рецепторы, нацеленные на adgre2 и/или clec12a, способ ее получения и ее применение, фармацевтическая композиция
HK40001773A (en) Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260402